Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndromes

American Journal of Hematology

Volumn 57, Issue 2, 1998, Pages 113-118

  Piedras, Josefa ^a   Hernández, Guadalupe ^a   López Karpovitch, Xavier ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Androgens; Anemia; Aplastic; Erythropoietin; Myelodysplastic syndromes

Indexed keywords

ANDROGEN; HEMOGLOBIN; MESTEROLONE; OXYMETHOLONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR;

ANDROGEN THERAPY; ANEMIA; APLASTIC ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROPOIESIS; FEMALE; HEMATOCRIT; HORMONE RELEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETICULOCYTE COUNT; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; ANDROGENS; ANEMIA, APLASTIC; ERYTHROPOIETIN; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 2642621557     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199802)57:2<113::AID-AJH4>3.0.CO;2-Z     Document Type: Article

References (42)

1. Spivak JL: The mechanism of action of erythropoietin. Int J Cell Cloning 4:139-166, 1986.
2. Shahidi NT: Androgens and erythropoiesis. N Engl J Med 289:72-80, 1973.
3. Neff MS, Goldberg J, Slifkin RF, Eiser AR, Calamia V, Kaplan M, Baez A, Gupta S, Mattoo N: A comparison of androgens for anemia in patients on hemodialysis. N Engl J Med 304:871-875, 1981.
4. Sánchez-Medal L, Gómez-Leal A, Duarte-Zapata L: Anabolic therapy in aplastic anemia. Blood 28:979, 1966.
5. Duarte L, Sandoval RL, Esquivel F: Androstane therapy of aplastic anaemia. Acta Haematol 47:140-145, 1972.
6. Romero-García F, Rosales-Hernández JJ: Empleo de la oximetolona a dosis bajas en el tratamiento de la anemia refractaria: Informe preliminar. Sangre 10:365-375, 1965.
7. Gurney CW, Fried W: Further studies on the erythropoietic effect of androgens. J Lab Clin Med 65:775-782, 1965.
8. Fried W, Gurney CW: Use of mild plethora to demonstrate an erythropoietic effect from small amounts of androgens. Proc Soc Exp Biol Med 120:519-523, 1965.
9. Mirand EA, Gordon AS, Wenig J: Mechanism of testosterone action in erythropoiesis. Nature 206:270-272, 1965.
10. Gordon AS, Mirand EA, Wenig J: Androgen actions on erythropoiesis. Ann NY Acad Sci 149:318-335, 1968.
11. Miller ME, Chandra M, Garcia JF: Clinical applications of measurement of serum immunoreactive levels of erythropoietin. Ann NY Acad Sci 459:375-381, 1985.
12. Hellebostad M, Haga P, Cotes PM: Serum immunoreactive erythropoietin in healthy normal children. Br J Haematol 70:247-250, 1988.
13. Pavlovic-Kentera V, Milenkovic P, Ruvidic R, Jovanovic V, Biljanovic-Paunovic L: Erythropoietin in aplastic anaemia. Blut 39:345-350, 1979.
14. Takeichi N, Umemura T, Nishimura J, Motomura S, Kozura M, Ibayashi H: Regulation of erythropoietin and burst-promoting activity production in patients with aplastic anaemia and iron deficiency anaemia. Acta Haematol 80:145-152, 1988.
15. Wognum AW, Lansdorp PM, Eaves AC, Krystal G: An enzyme-linked immunosorbent assay for erythropoietin using monoclonal antibodies, tetrameric immune complexes, and substrate amplification. Blood 74:622-628, 1989.
16. Mason Garcia M, Beckman BS, Brookins JW, Powell JS, Lanham W, Blaisdell S, Keay L, Li SC, Fisher JW: Development of a new radio-immunoassay for erythropoietin using recombinant erythropoietin. Kidney Int 38:969-975, 1990.
17. Schrezenmeier H, Noé G, Raghavachar A, Rich IN, Heimpel H, Kubanek B: Serum erythropoietin and serum transferrin receptor levels in aplastic anaemia. Br J Haematol 88:286-294, 1994.
18. Hellström-Lindberg E: Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 89:67-71, 1995.
19. de Klerk G, Rosengarten PCJ, Vet JWM, Goudsmit R: Serum erythropoietin (ESF) titres in anemia. Blood 58:1164-1170, 1981.
20. Jacobs A, Janowska-Wieczorek A, Caro J, Bowen DT, Lewis T: Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 73:36-39, 1989.
21. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrman F, Freund M, Meusers P, Salama A, Heimpel H: Treatment of aplastic anaemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 324:1297-1304, 1991.
22. Bennett JM, Catovsky D, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the myelodysplasic syndromes. Br J Haematol 51:189-199, 1982.
23. Piedras J, Reyes-Devesa S, Cordova MS, Chavez L: Límites de referenda de serie roja, obtenidos en el equipo Coulter S-Plus STKR, en adultos sanos residentes a 2,240 metros sobre el nivel del mar. Rev Invest Clin 43:174-178, 1991.
24. Alvarez X, Piedras J, Cordova MS. López-Karpovitch X, Cano R: Ferritina sérica en mujeres y varones. Valores de referenda. Rev Invest Clin 33:13-16, 1981.
25. Milledge JS, Cotes PM: Serum erythropoietin in humans at high altitude and its relation to plasma renin. J Appl Physiol 59:360-364, 1985.
26. Cazzola M, Beguin Y: New tools for clinical evaluation of erythron function in man. Br J Haematol 80:278-284, 1992.
27. Musto P, Modoni S, Alicino G, Savino A, Longo A, Bodenizza C, Falcone A, D'Arena G, Scalzulli P, Perla G, Casparrini G, Carotenuto M: Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes. Haematologica 79:493-499, 1994.
28. Weber JP, Walsh PC, Peters CA, Spivak JL: Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hematol 36:190-194, 1991.
29. Wolfson M, Mundt DJ, Hawley GG: Recombinant human erythropoietin utilization in Department of Veterans Affairs Dialysis Units. Am J Kidney Dis 24:184-191, 1994.
30. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ: Xndrogens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 17:29-33, 1991.
31. Ireland RM, Atkinson K, Concannon A, Dodds A, Downs K, Biggs JC: Serum erythropoietin changes in autologous and allogeneic bone marrow transplant patients. Br J Haematol 76:128-134, 1990.
32. Bjarnason I, Cotes PM, Knowles S, Reid C, Wilkins R, Peters TJ: Giant lymph node hyperplasia (Castleman's disease) of the mesentery. Observations on the associated anemia. Gastroenterology 87:216-223, 1984.
33. Stohlman F, Jr., Brecher G: Humoral regulation of erythropoiesis. V. Relationship of plasma erythropoietin level to bone marrow activity. Proc Soc Exp Biol Med 100:40-44, 1959.
34. McGonigle RJS, Ohene-Frempong K, Lewy JE, Fisher JW: Erythropoietin response to anaemia in children with sickle cell disease and Fanconi's hypoproliferative anaemia. Acta Haematol 74:6-9, 1985.
35. Huebers HA. Beguin Y, Pootrakul P, Einspahr D, Finch CA: Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 75:102-107, 1990.
36. Flowers CH, Skikne BS, Covell AM, Cook JD: The clinical measurement of serum transferrin receptor. J Lab Clin Med 114:368-377, 1989.
37. Hillman RS, Finch CA, eds. "Red Cell Manual." Philadelphia: Davis, 1985.
38. Beguin Y, Clemons GK, Pootrakul P, Fillet G: Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 81:1067-1076, 1993.
39. Bowen DT, Culligan D, Beguin Y, Kendall R, Willis N: Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters. Leukemia 8:151-155, 1994.
40. Cazzola M, Ponchio L: Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Blood 80:841-843, 1992.
41. Cazzola M, Ponchio L, Beguin Y, Rosti V, Bergamaschi G, Liberato NL, Fregoni V, Nalli G, Barosi G, Ascari E: Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 79:29-37, 1992.
42. Bessho M, Jinnai I, Matsuda A, Saito M, Hirashima K: Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Cloning 8:445-458, 1990.